IDH1 and glioblastoma: Indeed, the inhibition of IDH1, both genetic or pharmacologically, leads to a decrease in GBM cell growth and higher sensitivity to RTK‐targeted therapies, increasing the survival of mice with patient‐derived GBM cells xenografts [34].